Interleukin‐2 deprived state of regulatory T cells and their recovery by low‐dose interleukin‐2 in patients with inflammatory myopathies | Synapse
March 28, 2026Open Access
Interleukin‐2 deprived state of regulatory T cells and their recovery by low‐dose interleukin‐2 in patients with inflammatory myopathies
Key Points
The research aims to understand the role of interleukin-2 (IL-2) in regulatory T cell (Treg) function in inflammatory myopathies.
Analysis of interleukin-2 levels in patients with polymyositis and dermatomyositis.
Assessment of regulatory T cell populations and their functional status.
Evaluation of the effects of low-dose interleukin-2 therapy on Treg recovery.
IL-2 deficiency was found to have significant implications in the pathophysiology of PM/DM.
Low-dose IL-2 therapy led to recovery and expansion of Treg populations.
Improvement in Treg functionality was observed following IL-2 treatment.
Abstract
Our data suggest that shortage of IL-2 is pathophysiologically relevant in PM/DM. Recovery and expansion of Treg by low-dose IL-2 therapy could thus be a promising targeted treatment option.